← Leaderboards
Ronald J Biediger
Texas Heart Institute
$2,043,958
Attributed
$4,753,357
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2022–25$2.5M$1.9M$1.3M$625K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$4,753,357 · 4
By mechanism
R42$1,996,323 · 1
R33$1,628,403 · 2
R61$1,128,631 · 1
Top collaborators
- Darren G Woodside5 shared
- George Holland2 shared
- Peter Vanderslice2 shared
Most similar at Texas Heart Institute
Same institution · by research overlap
- Darren G Woodside$3,775,052
Others in their field
Other Rising Stars on “Dose”
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Suma Babu · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Supriya Menezes · The Emmes Company, Llc$18,394,958
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Dawn Fallacara · Battelle Centers/Pub Hlth Res & Evaluatn$13,673,728
Research focus
DoseGrantResponseSmall MoleculeBiological ProductsClinical TrialsPharmaceutical PreparationsProgramsDrug KineticsLeadCellsIntegrinsFutureLinkAdhesion ReceptorCaringInflammatoryMediatingAwardDesignAnalogLead SeriesAntagonistFunding Opportunities
Grant awards (7)
Targeting Integrin Signaling in Atherosclerosis$534,347
R33 · FY2025 · HL
Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD$959,682
R42 · FY2024 · DK
Targeting Integrin Signaling in Atherosclerosis$556,549
R61 · FY2024 · HL
Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD$1,036,641
R42 · FY2023 · DK
Targeting Integrin Signaling in Atherosclerosis$572,082
R61 · FY2023 · HL
Optimization of small molecule integrin activators to enhance cord blood transplant$547,028
R33 · FY2023 · HL
Optimization of small molecule integrin activators to enhance cord blood transplant$547,028
R33 · FY2022 · HL